Advertisement

Adjuvant chemotherapy and hypofractionated whole breast cancer radiotherapy: Is it time to rethink the sequencing?

Published:October 17, 2022DOI:https://doi.org/10.1016/j.radonc.2022.10.012
      In regard to the article on DBCG 82bc trial [
      • Overgaard M.
      • Nielsen H.M.
      • Tramm T.
      • Højris I.
      • Grantzau T.L.
      • Alsner J.
      • et al.
      Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial.
      ], an important milestone has been reached, because it has definitely demonstrated the benefits of PMRT at 30-year long-term. Looking ahead, several considerations should be done in light of the advantages of the new breast radiation schedules.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Overgaard M.
        • Nielsen H.M.
        • Tramm T.
        • Højris I.
        • Grantzau T.L.
        • Alsner J.
        • et al.
        Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial.
        Radiother Oncol. 2022; 170: 4-13https://doi.org/10.1016/j.radonc.2022.03.008
        • START Trialists' Group
        • Bentzen S.M.
        • Agrawal R.K.
        • Aird E.G.
        • Barrett J.M.
        • Barrett-Lee P.J.
        • et al.
        The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
        Lancet Oncol. 2008; 9: 331-341https://doi.org/10.1016/S1470-2045(08)70077-97
        • START Trialists’ Group
        • Agrawal R.K.
        • Aird E.G.
        • Barrett J.M.
        • Barrett-Lee P.J.
        • et al.
        The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
        Lancet. 2008; 371: 1098-1107https://doi.org/10.1016/S0140-6736(08)60348-7
        • Whelan T.J.
        • Pignol J.-P.
        • Levine M.N.
        • Julian J.A.
        • MacKenzie R.
        • Parpia S.
        • et al.
        Long-term results of hypofractionated radiation therapy for breast cancer.
        N Engl J Med. 2010; 362: 513-520https://doi.org/10.1056/NEJMoa0906260
        • Liu L.
        • Yang Y.
        • Guo Q.
        • Ren B.
        • Peng Q.
        • Zou L.
        • et al.
        Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review.
        Radiat Oncol. 2020; 15: 17https://doi.org/10.1186/s13014-020-1463-1
        • Murray Brunt A.
        • Haviland J.S.
        • Wheatley D.A.
        • Sydenham M.A.
        • Alhasso A.
        • Bloomfield D.J.
        • et al.
        Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
        Lancet. 2020; 395: 1613-1626https://doi.org/10.1016/S0140-6736(20)30932-6
        • Krug D.
        • Baumann R.
        • Krockenberger K.
        • Vonthein R.
        • Schreiber A.
        • Boicev A.
        • et al.
        Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial.
        Strahlentherapie und Onkologie. 2021; 197: 48-55https://doi.org/10.1007/s00066-020-01689-7
        • Levens Y.
        Hypofractionated breast radiotherapy : financial and economical consequences.
        Breast. 2010; 19: 192-197https://doi.org/10.1016/j.breast.2010.03.003
        • Dwyer P.
        • Hickey B.
        • Burmeister E.
        • Burmeister B.
        Hypofractionated whole-breast radiotherapy: impact on departmental waiting times and cost.
        J Med Imaging Radiat Oncol. 2010; 54: 229-234https://doi.org/10.1111/j.1754-9485.2010.02163.x
        • Arcangeli G.
        • Pinnarò P.
        • Rambone R.
        • Giannarelli D.
        • Benassi M.
        A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
        Int J Radiat Oncol Biol Phys. 2006; 64: 161-167https://doi.org/10.1016/j.ijrobp.2005.06.040
        • Bellon J.R.
        • Come S.E.
        • Gelman R.S.
        • Henderson I.C.
        • Shulman L.N.
        • Silver B.J.
        • et al.
        Sequencing of Chemotherapy and Radiation Therapy in Early-Stage Breast Cancer: Updated Results of a Prospective Randomized Trial.
        J Clin Oncol. 2005; 23: 1934-1940https://doi.org/10.1200/JCO.2005.04.032
        • Cuzick J.
        • Stewart H.
        • Rutqvist L.
        • Houghton J.
        • Edwards R.
        • Redmond C.
        • et al.
        Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.
        J Clin Oncol. 1994; 12: 447-453https://doi.org/10.1200/JCO.1994.12.3.447
        • Recht A.
        • Come S.E.
        • Henderson I.C.
        • Gelman R.S.
        • Silver B.
        • Hayes D.F.
        • et al.
        The sequencing of chemotherapy and radiation therapy after conservative surgery for earlystage breast cancer.
        N Engl J Med. 1996; 334: 1356-1361https://doi.org/10.1056/NEJM199605233342102
        • Buus R.
        • Sestak I.
        • Kronenwett R.
        • Ferree S.
        • Schnabel C.A.
        • Baehner F.L.
        • et al.
        Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
        J Clin Oncol. 2021; 39: 126-135https://doi.org/10.1200/JCO.20.00853
        • Formenti S.C.
        • Demaria C.
        Local control by radiotherapy: is that all there is?.
        Breast Cancer Res. 2008; 10: 215https://doi.org/10.1186/bcr2160